drugset
drugset / Trial / NCT00207025

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

NCT00207025 ↗

Phase 1 Terminated 60 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.

Timeline

Start
2004-10
Primary completion
2007-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-275183 Small molecule — —

Indications

neoplasm